Rifamycin SV Sodium

• CAT Number: R011341
• CAS Number: 14897-39-3
• Molecular Formula: C37H46NO12 • Na
• Molecular Weight: 719.80
• Purity: ≥95%
• Synonyms: 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-Acetate Sodium Salt; Rifamastene; Rifocin; Tuborin
• Target: Bacterial
• Storage: -20°C
• IUPAC Name: sodium;(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-27-olate
• InChI: InChI=1S/C37H47NO12.Na.H2O/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41;;/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46);;1H2/q;+1;/p-1/b11-10+,14-13+,17-12-;;/t16-,18+,19+,20+,25-,29-,30+,33+,37-;;/m0../s1
• InChIKey: YVOFSHPIJOYKSH-NLYBMVFSSA-M
• SMILES: C[C@H]1/C=C/C=C(\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)[O-])/C.[Na+]

Rifamycin SV Sodium（Cat No.:R011341）is a semi-synthetic antibiotic derived from Amycolatopsis mediterranei, belonging to the rifamycin family. It is primarily used to treat bacterial infections, particularly targeting Mycobacterium tuberculosis and Staphylococcus aureus. Rifamycin SV works by inhibiting bacterial RNA synthesis through binding to RNA polymerase, effectively halting protein synthesis. This antibiotic is valued in both clinical settings for its role in treating tuberculosis and other resistant infections, as well as in research for studying RNA transcription processes. Its stability in sodium form enhances solubility and delivery in pharmaceutical applications.

Overview of Clinical Research

Rifamycin SV sodium is a DNA-directed RNA polymerase inhibitor developed by Cosmo Pharmaceuticals. It was registered for Traveller's diarrhoea in Italy.

Reference

1.Riva, S., and Silvestri, L.G. Rifamycins: A general view. Annu. Rev. Microbiol. 26, 199-224 (1982).
2.Kohanski, M.A., Dwyer, D.J., and Collins, J.J. How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol. 8(6), 423-435 (2010).